Drugs & Targets Keytruda becomes first anti-PD-1 therapy to receive a CHMP positive opinion for previously untreated NSCLC December 16, 2016Vol.42 No.46
Drugs & Targets Verastem licenses exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. December 11, 2016Vol.42 No.42
Drugs & TargetsFree Avastin Plus Chemo Gets FDA Approval for a Type of Ovarian Cancer December 09, 2016Vol.42 No.45
Drugs & Targets First computer-aided detection system gets FDA approval December 02, 2016Vol.42 No.44
